Gordon Fox • June 27, 2023
Patient Education Committee Update

The Patient Education Committee has been busy in recent months! Some of the projects we’re working on or planning include:

Caregiver education :

We will develop guides to help family members, and friends know when patients need help and what steps (emergency room, call the doctor, additional medications) to take if they do.

Decision making:

  • Understanding medical strategies: We will develop materials to help patients understand how doctors make medical decisions. For example, how do they decide to recommend (or not recommend) an ICD implantation or myectomy? And how should patients make their own decisions about these recommendations?
  • Personal decisions that are affected by HCM: Many decisions HCM patients need to make aren’t one-size-fits-all. For example, should I have a child? Should I accept the offer of a job with physical challenges? We will be developing materials aimed at helping think out these decisions by examining their consequences, using decision trees.

There are a number of other things in the hopper. We are discussing ways to use new forums and new approaches to reach people who may have HCM. And in the not-too-distant future, watch for an update on our website! We are always happy to listen to suggestions, whether big (new projects) or small (say, an error on the website).

If there is a resource that you would find helpful, please email  elena@4hcm.org , and she will forward it to the HCMA Patient Education Committee. 

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts